Results 171 to 180 of about 1,118,702 (266)

The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group.

J Clin Endocrinol Metab
Bulaicon OO, van Haalen FM, Clunie GPR, Grasemann C, Lems WF, Makras P, Mortier G, Oheim R, Raimann A, Siggelkow H, Tabacco G, van der Wal RJP, de Witte PB, Appelman-Dijkstra NM.   +13 more
europepmc   +1 more source

Gellan Gum Fluid Gel System for Controlled‐Delivery of Cytokine‐Licensed MSC‐EVs to Enhance Corneal Repair in Limbal Stem Cell Deficiency

Advanced Healthcare Materials, EarlyView.
Gellan gum fluid gel (FG) enables controlled ocular delivery of mesenchymal stromal cell (MSC)‐derived extracellular vesicles (EV). Its shear‐thinning, solid‐liquid‐solid rheology ensures prolonged ocular retention. Sustained MSC‐EV release (∼18% in 6 hrs) supports effective EV ocular delivery.
Seyedmohammad Moosavizadeh, Ava Dashti, Thomas E. Robinson, Robyn Gaffey, Richard Moakes, Neil Lagali, Liam Grover, Thomas Ritter   +7 more
wiley   +1 more source

Uncoupled bone remodeling drives myeloma bone disease in Vk*MYC mouse model of multiple myeloma. [PDF]

Bone Rep
Schmal C, Simic MK, Xiao Y, Catala AA, Jiang M, Andersen TL, Diaz-delCastillo M, Croucher P, McDonald M, Jafari A.   +9 more
europepmc   +1 more source

Therapeutic Extracellular Vesicles from Synovial Fibroblast‐Primed MSCs for Osteoarthritis Treatment

Advanced Healthcare Materials, EarlyView.
EVs derived from the microenvironment of SFs transferred MSCs (miSF‐MSC‐EVs) enhanced the expression of miRNAs that regulate cell migration, cell adhesion, and the TGF‐β signaling pathway, demonstrating superior anti‐inflammatory and cartilage regeneration effects compared to conventional MSC‐EVs.
Seo Jeong Kim, Ji Seob Kim, Min Hee Moon, Jae‐Hyeok Jang, In Sun Hwang, Byung‐Hyun Cha   +5 more
wiley   +1 more source

Osteoporosis and CKD-Metabolic Bone Disease Under the Same Umbrella: Insights From a Joint Scientific Symposium. [PDF]

Kidney Int Rep
Dempster DW, Evenepoel P, Nickolas TL, Massy ZA, Mazzaferro S, Harvey NC, Miller PD, Pazianas M.   +7 more
europepmc   +1 more source

POSS‐PEG‐NHS and GSH Cocrosslink DPAV to Prepare Anticalcification Bioprosthetic Scaffold With Enhanced Reendothelization, Anti‐inflammation, and Anti‐ROS

Advanced Healthcare Materials, EarlyView.
POSS‐PEG‐NHS and GSH cocrosslinked DPAV to prepare a multifunctional anticalcification valve substitute. This modification enhances mechanical properties, hemocompatibility, and re‐endothelialization while promoting anti‐inflammatory M2 macrophage infiltration and reducing calcification.
Yuqing Zhang, Chen Qian, Yingjie He, Jingli Ding, Binhao Zhang, Minghui Zou, Xing Chen, Jinping Zhao, Cuifen Lu, Jinping Liu, Jianliang Zhou   +10 more
wiley   +1 more source

Aggressive Systemic Mastocytosis Presenting as Diffuse Osteoblastic Bone Disease: A Diagnostic Pitfall Mimicking Metastatic Cancer. [PDF]

Eur J Case Rep Intern Med
Melício A, Gonçalves HD, Dias M, Vasconcelos-Teixeira S, Madeira Lopes J.   +4 more
europepmc   +1 more source

Gardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden

Advanced Healthcare Materials, EarlyView.
Nanoemulsion delivery of a TLR7 agonist enhances safety and promotes colocalization with Leishmania‐infected macrophages in skin lesions, enabling a ∼2‐log reduction in parasite burden. However, tissue‐level constraints and TLR‐driven regulatory feedback generate a mixed immune response that limits complete parasite clearance.
Carmen Palomino‐Cano, M. Carmen Mera‐Delgado, Esther Moreno, Esther Larrea, Lecnia Aguirre, Jonathan Miguel Zanatta, Sónia Barros‐Carvalho, Iola F. Duarte, Ricardo Silvestre, Juan M. Irache, Javier Carrión, Socorro Espuelas   +11 more
wiley   +1 more source

Osteosclerotic Bone Disease Due to Skeletal Fluorosis in a Father-Son Pair. [PDF]

AACE Endocrinol Diabetes
Nandakumar D, Cherian KE.
europepmc   +1 more source